Bioavailability & Bioequivalence studies of Biopharmaceuticals

The assessment of BA/BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. Should the rate of absorption actually differ between products, it would have to be intentional and reflected in the proposed product label and be clearly demonstrated that it is not essential in the attainment of effective body drug concentrations on chronic use or has been shown to be medically insignificant for the drug. In practice, equivalence is indicated when key pharmacokinetic parameters used to establish rate and extent of the test, and reference products fall within a present confidence interval. The FDA declares a drug product to be therapeutically equivalent to the innovator product if it is pharmaceutically equivalent, i.e., same active ingredient, dosage form, strength and route of administration, and bioequivalent. Products that are therapeutically equivalent can be used interchangeably. Thus, BE studies are construed to be considered surrogates for comparative clinical trials for the assessment of therapeutic equivalence in safety and efficacy between two drug products.

  • Drug Absorption and Distribution
  • Bioequivalence Protocols : In vitro-In vivo correlation
  • Dissolution Studies
  • PK/PD studies

Related Conference of Bioavailability & Bioequivalence studies of Biopharmaceuticals

November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
March 13-14, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
July 24-25, 2025

5th World Congress on Cardiovascular Medicine Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
October 22-23, 2025

7th European Conference on Advance Clinical Trials and Research

Aix-en-Provence, France

Bioavailability & Bioequivalence studies of Biopharmaceuticals Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in